Tasly Mauna Kea Medical Engineering Technology Co. will expand reach of Cellvizio in China and launch a dedicated platform for neurosurgical applications worldwide French firm Mauna Kea Technologies, inventor of Cellvizio- the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, and China-based Tasly Pharmaceutical Group have announced the achievement of a new key milestone in their strategic partnership. Cellvizio technology uniquely delivers in vivo cellular visualisation which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. Tasly Mauna Kea Medical Engineering Technology Co., based in the Zheijang province of China, is now legally incorporated with registered capital of RMB 250 million (EUR 35 million). The joint venture (JV) will serve as the exclusive commercial platform for expanding the reach of Cellvizio into the Chinese domestic market and will launch a dedicated platform for neurosurgical applications worldwide.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!